Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Mallinckrodt
Teva
Healthtrust
Cipla
Accenture
Johnson and Johnson
Queensland Health
Chinese Patent Office

Generated: April 25, 2018

DrugPatentWatch Database Preview

XURIDEN Drug Profile

« Back to Dashboard

When do Xuriden patents expire, and when can generic versions of Xuriden launch?

Xuriden is a drug marketed by Wellstat Therap and is included in one NDA. There is one patent protecting this drug.

This drug has one hundred and seventy-five patent family members in twenty-one countries.

The generic ingredient in XURIDEN is uridine triacetate. There are thirty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the uridine triacetate profile page.
Summary for XURIDEN
Drug patent expirations by year for XURIDEN
Pharmacology for XURIDEN
Synonyms for XURIDEN
(2R,3R,4R,5R)-2-(ACETOXYMETHYL)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)TETRAHYDROFURAN-3,4-DIYL DIACETATE
[(2R,3R,4R,5R)-3,4-diacetoxy-5-(2,4-dioxopyrimidin-1-yl)tetrahydrofuran-2-yl]methyl acetate
[(2R,3R,4R,5R)-3,4-diacetyloxy-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl acetate
105T388
2 ,3 ,5 -Triacetyluridine
2',3',5'-Tri-O-acetyluridine
293738-13-3
2WP61F175M
4105-38-8
AC1L2FGB
AK-73070
AKOS015964563
AN-158
ANW-29551
API0001026
AUFUWRKPQLGTGF-FMKGYKFTSA-N
AX8007900
CHEBI:90914
CHEMBL2107381
CTK3J5861
D09985
D0OL7F
DB09144
EINECS 223-881-5
FT-0081134
J-700012
KSC495Q6D
MFCD00023795
MLS006009982
MolPort-005-940-324
NU000494
PN 401
PN401
PubChem14176
RG 2133
SCHEMBL871011
SMR004701034
SY004945
Tri-O-acetyluridine
Triacetyluridine
UNII-2WP61F175M
URI007
Uridine 2',3',5'-triacetate
Uridine triacetate
Uridine triacetate (USAN/INN)
Uridine triacetate [USAN:INN]
Uridine, 2',3',5'-triacetate
Vistonuridine
Xuriden (TN)
ZINC3843198

US Patents and Regulatory Information for XURIDEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wellstat Therap XURIDEN uridine triacetate GRANULE;ORAL 208169-001 Sep 4, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Wellstat Therap XURIDEN uridine triacetate GRANULE;ORAL 208169-001 Sep 4, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Wellstat Therap XURIDEN uridine triacetate GRANULE;ORAL 208169-001 Sep 4, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for XURIDEN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,166,581 Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides ➤ Try a Free Trial
7,105,498 Acylated uridine and cytidine and uses thereof ➤ Try a Free Trial
6,020,322 Acyl deoxyribonucleoside derivatives and uses thereof ➤ Try a Free Trial
5,968,914 Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for XURIDEN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017 00036 Denmark ➤ Try a Free Trial PRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF TIPIRACIL; REG. NO/DATE: EU/1/16/1096 20160427
0889 Netherlands ➤ Try a Free Trial PRODUCT NAME: TRIFLURIDINE IN COMBINATIE MET TIPIRACILHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1096 20160427
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Julphar
US Department of Justice
Healthtrust
Federal Trade Commission
Covington
Farmers Insurance
Queensland Health
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.